The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Griffin Mining, Energy XXI

Thu, 06th May 2010 12:49

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008.The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $25.4m from $32.1m.Griffin said it shut down Caijiaying in the first half the year, which enabled it to improve the mine's efficiency once it re-opened in the second half and metals prices had recovered.Bermuda-based oil group Energy XXI saw third quarter earnings before interest, taxes, depreciation, depletion and amortization rise by a third from the same period a year ago to $87.3m.'This quarter's results benefitted from our December consolidation of interests in our key Gulf of Mexico shelf properties and reflect the advantage of having an oil-focused production portfolio,' chairman and chief executive John Schiller said.Investors have welcomed news that respiratory disease drug developer Synairgen's inhaled interferon beta (IFN-beta) to treat rhinovirus infections in asthma and chronic obstructive pulmonary disease (COPD) has been granted in Europe."The European patent grant and the US patent granted last year are key ingredients in the out-licensing package," said chief executive Richard Marsden.Deltex Medical, whose Oesophageal Doppler monitoring equipment is used to measure blood flow in surgery patients, has received a forward order for probes worth at least $204,000 over the next six months. The disposable probes, used with Deltex's CardioQ-ODM system, are placed into the oesophagus through either the mouth or nose and help calculate how quickly blood is flowing. A reduction in circulating blood volume can be deadly.South Africa-focused ferrochrome producer International Ferro Metals, which has its head office in Sydney, thinks it will not be affected by Australia's proposals for a supertax on mining companies.'As all of IFL's operations and resources are located in South Africa with no mining activities undertaken in Australia, IFL believes, having consulted with its advisors, that it will not be liable for the newly proposed resource rent tax,' it says. Personnel software provider Allocate Software has bought Dynamic Change, a compliance and performance management software developer focused on the UK healthcare market. Allocate will pay up to £9m over three years for Dynamic Change, with £4.9m in cash and £0.1m in shares being paid upfront. The company is being acquired with cash balances and receivables of around £1.6m, largely reflecting deferred income which arises from subscriptions paid annually in advance. Clapham House, the restaurant group that owns the Gourmet Burger Kitchen (GBK) brand, is to raise £2.2m from a placing of 3.73m shares at 60p each. The funds will be used to accelerate the expansion of the GBK chain.Product development software specialist Sopheon has sealed 12 new and extension licence orders so far in 2010. Since the company's last trading update on 24 March revenue visibility for the full year from contracted business and recurring revenue streams has risen to £5.6m from £4.8m.
More News
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.